Marinomed Biotech AG · VIE:MARI

Marinomed Biotech — Fact Sheet (March 2024)

19 slides from Marinomed Biotech's fact sheet, March 2024

  1. Slide 1: Budesolv

    Budesolv Low-dose anti-allergic corticosteroid nasal spray with immediate relief March 2024

  2. Slide 2: Disclaimer

    Disclaimer These materials (the “Presentation”) have been provided to you by Marinomed Biotech AG together with its respective members, directors, officers, employees, advisers or agents (together “Marinomed”) in connection with a potential transaction relating to Marinomed’s asset Budesolv (the “Tr

  3. Slide 3: Marinomed at a glance

    Marinomed at a glance / 0) Marinomed

  4. Slide 4: Marinomed at a glance

    Marinomed at a glance Publicly listed biopharmaceutical company in Austria 2006 2008 2016 2019 2021 2022 Foundation Launch of Carragelose Invention of IPO and Marinosolv Marinosolv deal and Deal with Marinosolv clinical validation Solv4U launch Procter & Gamble Therapeutic areas VIROLOGY IMMUNOLOGY

  5. Slide 5: Business Model

    Business Model IP generation with lean organization & grow existing business RESEARCH & DEVELOPMENT SALE OF GOODS Research & Pre-clinical Early clinical Supply chain Innovation development development organization Intellectual property High-value products Revenue through license deals Revenue throug

  6. Slide 6: Platforms & Therapeutic Areas

    Platforms & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & Allergy Eye drops Budesolv Tacrosolv Solv4U cold portfolio nasal spray Dry, irritated eyes A

  7. Slide 7: Budesolv

    Budesolv The only low-dose intranasal, preservative free corticosteroid with strong symptom relief after first dose Erich Durchschlag Marinomed Biotech AG s. Business Development Mgr. Hovengasse 25 +43 676 3253005 2100 Korneuburg, Austria [email protected] © Marinomed Biotech AG 7

  8. Slide 8: Executive summary: Budesolv

    Executive summary: Budesolv Innovative opportunity with strong USP to challenge the total allergic rhinitis market Budesolv Market opportunity Regulatory path Business model • Fast and strong efficacy after first dose • Fast growing (~4,5% • Hybrid application in EU • Classical license deal • Strong

  9. Slide 9: Marinosolv platform technology

    Marinosolv® platform technology Formulation technology Capabilities / improvements • Solubilization of poorly water-soluble compounds • Significantly increases bioavailability • Allows dose reduction & faster onset of action • Reduces pharmaceutical compounds in wastewater • Clinically validated & p

  10. Slide 10: Budesolv nasal spray

    Budesolv nasal spray The only nasal spray providing solubilized corticosteroid Benefits of the solution • Highly increased bioavailability • Fast onset of action after first dose • Low dose application (~16% of originator) • Preservative - free formulation • Easy to use - no shaking, high-precision

  11. Slide 11: Pathophysiology of Allergic Rhinitis (AR)

    Pathophysiology of Allergic Rhinitis (AR) IgE/allergen (FcεRI) complex binding to mast cells causes release of histamines and pro-inflammatory cytokines Block Histamine release with Anti-histamines Allergic reaction triggered by IgE plus allergen complex Block inflammatory processes with Steroids e.

  12. Slide 12: Allergic Rhinitis market

    Allergic Rhinitis market Huge market potential for innovative drugs in a growing market Highest growth for antihistamines & corticosteroids Overall growth of global allergic rhinitis market 15.4bn US$ 11.4bn US$ +4.0bn US$ 1.2 Antihistamines 1.3 Decongestants 2023 4.7 Corticosteroids 2030 7.7 4.8 3.

  13. Slide 13: Medical need in Allergic Rhinitis (AR)

    Medical need in Allergic Rhinitis (AR) Range of therapies available, but high unmet medical need remains Antihistamines Corticosteroids Immunotherapy The unmet medical need in allergic rhinitis Effectiveness Marketed steroid drugs have slow onset of action Onset of action Antihistamines are less eff

  14. Slide 14: Primary endpoint: Non-inferiority

    Primary endpoint: Non-inferiority Budesolv clinically equivalent to the originator on day 8 in phase 3 study TNSS* Scores day 8 (n=75) Treatment Mean SD Median N Budesolv 10 4.98 2.57 4.47 75 Rhinocort 5.05 2.75 4.82 75 Aqua 64 Placebo 7.48 2.80 7.47 75 Budesolv 10 Rhinocort aqua 64 *TNSS = total na

  15. Slide 15: Key secondary endpoint: Fast onset of action TNSS

    Key secondary endpoint: Fast onset of action TNSS* Budesolv superior over originator on day 1 in phase 3 study TNSS onset day 1 TNSS before and after 0.5 treatment 7.6 0 7.4 7.2 TNSS -0.5 7 -1 6.8 TNSS 6.6 -1.5 6.4 0 30 60 90 120 150 180 210 240 6.2 min 6 5.8 Budesolv Placebo Rhinocort 5.6 Budesolv

  16. Slide 16: Budesolv positioning with strong USP(s) & high market potential

    Budesolv positioning with strong USP(s) & high market potential Budesolv: Competitor: Clear Suspension Budesolv Positioning Solution Bioavailability high low High bioavailability at low dose (tissue permeation) Onset of action hours 5-8 days First in class fast acting nasal spray Max. 40 µg Less sid

  17. Slide 17: Path to launch formulation and marketing authorization

    Path to launch formulation and marketing authorization Solutions to improve CIinical Phase 3 formulation manufacturing process and Further road towards MA insufficient stability at RT formulation • Metal free production • Oxygen-sealed packaging • Stable formulation at RT • APF pump • Stability test

  18. Slide 18: Timeline to obtain MA in EU & US

    Timeline to obtain MA in EU & US Q4 2023 AGES advised Plan EU +24 months +18 months Scientific Clinical Improvements advice phase 3 to formulation Meeting study and stability AGES Study Phase 3 chamber challenge study to Filing: MA & Dossier 11.12.2023 funding prove clinical efficacy EU hybrid (DCP)

  19. Slide 19: Budesolv

    Budesolv First low-dose intranasal corticosteroid with immediate relief after initial dose Erich Durchschlag Marinomed Biotech AG s. Business Development Mgr. Hovengasse 25 +43 676 3253005 2100 Korneuburg, Austria [email protected] © Marinomed Biotech AG 19

Marinomed Biotech — Fact Sheet (March 2024) on 6ix